Zacks.com releases the latest Analyst Interview. Today’s interview is with senior analyst Grant Zeng, who discusses Amgen (Nasdaq: AMGN), GlaxoSmithKline (NYSE: GSK) and Lexicon Pharmaceuticals Inc. (Nasdaq: LXRX).
A synopsis of today’s Analyst Interview is presented below. The full article can be read at www.zacks.com.
What aspects in the biotech market surprised you the most this year?
One surprise in the biotech market is the tightening of the safety issue. Two high profile cases were Amgen’s (Nasdaq: AMGN) blockbuster anemia drug Epogen/Aranesp and GlaxoSmithKline’s (NYSE: GSK) multibillion dollar diabetes drug Avandia. The FDA issued warnings for both drugs, leading to dramatically reduced sales this year. We expect the safety issue will once again impact the industry in 2008; individual companies will continue to have to deal with how to handle drug safety.
Do you have any top Buy recommendations to make for 2008 at this time?
For 2008, we have a Buy recommendation for Lexicon Pharmaceuticals Inc. (Nasdaq: LXRX). This is a small-cap biotech company specializing in gene-targeting technology. Using its proprietary “gene knockout” technology, the company has finished more than 82% of its Genome 5000 project so far, and has discovered more than 150 drug targets.
The company has initiated a 10TO10 drug development program, which means that the company will move 10 drug candidates into clinical development by 2010. We believe gene knockout technology is a viable platform and has advantages over traditional drug discovering technology to identify novel drug targets. We believe these advantages will contribute to better target selection and, therefore, to the success of Lexicon’s drug discovery and development efforts.
We believe the share price will continue to be volatile in 2008 due to its early stage of drug development and risks associated with drug research and development, but we also believe LXRX is an undervalued company based on its fundamentals. We encourage long-term investors to accumulate its shares at current levels, and our one-year price target is $6.5 per share.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2679.
The performance of the Zacks Rank portfolios shown above for annual and year-to-date periods are the linked monthly total returns (price changes + dividends) of equal weighted hypothetical portfolios, consisting of those stocks with the indicated Zacks Rank, assuming monthly rebalancing and zero transaction costs. These are not the returns of actual portfolios. The hypothetical portfolios were created at the beginning of each month from Jan 1988 forward based on the values of the Zacks Rank available to Zacks' clients before the beginning of each month. The portfolios created monthly from 1988 through September 2006 exclude ADRs and are comprised of stocks that have the indicated Zacks Rank and were covered by at least two analysts at the time of the stocks inclusion in the portfolio. Starting in October 2006 and going forward, the portfolios are comprised of all stocks with the indicated Zacks Rank and do not exclude ADRs, which is more reflective of the list of stocks that customers will find on the Zacks web sites. 2007 returns are for the period of Jan 1 – Jun 30, 2007. These performance numbers have been audited from 1995 through 2003 by Autschuler Melovan, a division of American Express Financial.